Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum

AUDUBON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, celebrated twenty years of the NuVasive XLIF procedure at the Society for Minimally Invasive Spine Surgery (SMISS) ’23 Annual Forum.

“Very few medical technology innovations have transformed an industry like the NuVasive XLIF procedure. Twenty years of XLIF has produced two decades of unmatched clinical validation, represented by an incredible body of evidence on the reproducibility, safety, and efficacy of the procedure,”^1-4 said Kyle Malone, senior vice president, Scientific Affairs of Globus Medical. “We have a true legacy to carry on as Globus Medical, and the focus on procedural innovation, surgeon partnership, research, and education that contributed to the success of XLIF will continue to guide future innovation while changing the lives of more patients around the globe.”

More than 120 surgeons and industry leaders gathered at SMISS to celebrate the XLIF procedure. Hosted by NuVasive, the evening event featured more than 20 surgeon speakers discussing the past, present and future impact of the procedure.

Dr. Frank Phillips, Rush University Medical Center, has been an XLIF user since 2003. “XLIF has been one of the most disruptive approaches to emerge in the spine field.” This surgical technique and its procedurally integrated portfolio of access, interbody implants, fixation and enabling technologies continue to demonstrate more predictable outcomes than traditional spinal fusion procedures, with substantially fewer complications.^5-9

“It’s remarkable how XLIF has continued to advance lateral, minimally invasive surgical applications,” said Dr. Bill Smith, neurosurgeon and early XLIF adopter who has completed over 1,800 XLIF procedures. “From its evolution of a one-level degenerative procedure to becoming the standard of care across multiple pathologies, XLIF has advanced patient care in historically challenging complex, deformity, tumor and trauma cases.”

With ~300,000 procedures performed, 200+ educational courses hosted, 600+ peer-reviewed publications, and 60+ dedicated products launched, XLIF continues to change patient lives.

“I look at what XLIF has done for minimally invasive surgery and single-position surgery, and I can only imagine what the future of innovation holds for the next twenty years in lateral,” said Dr. J. Alex Thomas, Atlantic Brain and Spine.

Learn more about the past, present and future of the XLIF procedure .

1. Sembrano JN, Tohmeh A, Isaacs R, et al. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis: part I: clinical findings. Spine 2016;41(Suppl 8):S123-S132.
2. Lehmen JA, Gerber EJ. MIS lateral spine surgery: A systematic literature review of complications, outcomes, and economics. Eur Spine J 2015;24(Suppl 3):287-313.
3. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J 2009;9(8):623-9.
4. Lucio JC, VanConia RB, Deluzio KJ, et al. Economics of less invasive spinal surgery: an analysis of hospital cost differences between open and minimally invasive instrumented spinal fusion procedures during the perioperative period. Risk Management and Healthcare Policy 2012;5:65-74.
5. Lehmen JA, Gerber EJ. MIS lateral spine surgery: A systematic literature review of complications, outcomes, and economics. Eur Spine J 2015;24(Suppl 3):287-313.
6. Cheng I, Briseno MR, Arrigo RT, et al. Outcomes of two different techniques using the lateral approach for lumbar interbody arthrodesis. Global Spine J 2015;5(4):308-14.
7. Khajavi K, Shen A, Lagina M, et al. Comparison of clinical outcomes following minimally invasive lateral interbody fusion stratified by preoperative diagnosis. Eur Spine J 2015;24(Suppl 3):322-30.
8. Okuda S, Miyauchi A, Oda T, et al. Surgical complications of posterior lumbar interbody fusion with total facetectomy in 251 patients. J Neurosurg Spine 2006;4(4):304-9.
9. Scaduto AA, Gamradt SC, Yu WD, et al. Perioperative complications of threaded cylindrical lumbar interbody fusion devices: anterior versus posterior approach. J Spinal Disord Tech 2003;16(6):502-7.
   
   
   
   

About Globus Medical, Inc.

Globus Medical is committed to providing innovative technologies and industry-leading clinical support to help surgeons and healthcare providers deliver better care around the globe. The Company provides one of the most comprehensive offerings of musculoskeletal solutions and enabling technologies to impact the care continuum, now including the procedurally integrated portfolio of NuVasive. The Company’s employees are relentlessly focused on advancing patient care. For more information, please visit

Safe Harbor Statements 

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, their businesses successfully and to achieve anticipated synergies, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at . Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.        

Investor contact:

Brian Kearns

610-930-1800

Media contact:

Melanie Ordoñez

858-722-3899